Abstract
Secondary extremity lymphedema is a chronic and progressive condition caused by obstructed lymphatic drainage, commonly following lymphadenectomy, infection, or trauma. Rodent models are preferred for experimental lymphedema research due to cost-effectiveness and reproducibility. Currently, rat tail models encounter limitations due to transient swelling and their inability to fully replicate the comprehensive pathophysiology of lymphedema, particularly concerning the effects of lymph node removal. We developed a series of rat tail lymphedema models incorporating skin resection, deep lymphatic vessel disruption, and gluteal lymph node (GLN) excision to assess effects on lymphatic architecture, inflammation, and fibrosis. Indocyanine green (ICG) lymphography was used to visualize lymphatic function. Tail volume and circumference were measured weekly, and histological assessments quantified fibrosis and fibroadipose thickening. Bulk RNA sequencing was performed to characterize the inflammatory processes triggered by GLN removal. The combined model resulted in severe and persistent lymphedema marked by progressive swelling and pronounced fibrosis. This lymphosome-based rat tail model successfully replicates key features of lymphedema, including sustained swelling, lymphatic disruption, inflammation, and fibrosis.
Introduction
Secondary lymphedema is a debilitating side effect of cancer treatments involving lymph node removal, characterized by chronic swelling, inflammation, and the accumulation of fibrotic tissue. While researchers frequently use rat tail models to study this condition, these models often fail to mimic the permanent damage seen in humans because rats have a high capacity for lymphatic regeneration. Most existing models focus solely on blocking lymphatic vessels while ignoring the regional lymph nodes, which clinical data suggests are critical triggers for chronic onset. This study introduces a "lymphosome-based" approach to create a more robust and clinically relevant animal model.
Methodology
The researchers utilized a lymphosome approach, targeting the specific anatomical territory drained by the Gluteal Lymph Nodes (GLNs). They compared several surgical variations in Sprague-Dawley rats, culminating in a "combined model" that integrated three techniques: circumferential skin resection, ligation of deep lymphatic vessels, and excision of the GLNs.
To evaluate the model's efficacy, the team employed Indocyanine Green (ICG) lymphography for real-time flow visualization, weekly morphometric analysis of tail volume, and histological staining (H&E and Masson’s trichrome) to quantify skin thickening and collagen deposition. Furthermore, bulk RNA-sequencing was performed to map the molecular pathways—specifically inflammation and immune response—triggered by the nodal excision.
Results and Key Insights
The Role of Nodal Disruption
The study's most significant finding was that removing the GLNs was the deciding factor for chronicity. Without node removal, the rats' lymphatic systems eventually bypassed surgical blockages. ICG imaging revealed that while the body attempted compensatory lymphangiogenesis toward the popliteal lymph nodes, this re-routing was insufficient to prevent chronic edema. Impaired vessels exhibited a "string-of-beads" appearance, indicating segmental dilation and stasis similar to human clinical observations.
Tissue Remodeling and Molecular Signatures
By week 6, histological analysis showed that groups with lymph node removal had the thickest fibroadipose layers and the highest levels of collagen deposition. The combined model (Skin + Deep + LN) showed the most severe swelling, which peaked at week 3 and remained significantly elevated throughout the 8-week study period. RNA-seq data confirmed that nodal removal triggered a massive inflammatory cascade involving the IL-17 and TNF signaling pathways, directly leading to permanent tissue thickening.
Discussion and Conclusion
This novel lymphosome-based model successfully replicates the chronic, progressive nature of human lymphedema. While rodents still possess a higher regenerative capacity than humans—evidenced by a slight reduction in volume after the initial peak—the model remains significantly more stable than previous iterations. This platform provides a superior foundation for testing advanced therapeutic interventions, such as Vascularized Lymph Node Transfer (VLNT) or decellularized scaffolds, aimed at reversing established fibrosis and inflammation.
Summary updated